Navigation Links
RedOak Logic's Mission: Transform Pharmaceutical Industry Drug Development

CARY, N.C., Aug. 17 /PRNewswire/ -- Exceptionally high costs.  Long research and development cycles.  Low success of clinical trials.  Slow and unpredictable regulatory reviews.  Dependence on out-dated information technology options.  It's not just time and money; there is also too much valuable information being wasted.  

Such justifiable criticisms of today's $800 billion drug development industry have led to the formation of a new company, RedOak Logic LLC, headquartered in Cary, North Carolina.  

RedOak Logic is developing an advanced decision modeling support platform and proprietary application interface -- an "Experience Management" solution -- tailored to the needs of the global drug development industry.  RedOak's solution is based on the Saffron Natural Intelligence Platform, the world's first commercial, scalable associative memory technology for sense-making, decision support and predictive analytics.  

"Let's face it: The current drug development model is broken. The amount of information drug companies must manage is unfathomable; they can't make sense of it all.  Current decision support and data analytics tools are inadequate.  As a result, the international drug development industry is underperforming.  RedOak Logic has been formed to deliver a Saffron-based Experience Management solution to redefine the way drug manufacturers bring products to market, so they can produce more effective drugs faster and more profitably," said Dale Fedewa, founder and CEO, RedOak Logic.  

Using RedOak's pharmaceutical industry solution, drug development companies will be able to capture and utilize all types of data -- public and proprietary, structured and unstructured  -- giving them unlimited capacity to make fully supported decisions on critical issues, such as:

  • Avoiding investments of time and resources in pursuit of ultimately unsuccessful drug candidates
  • Attaining meaningful and perceptive appreciation of safety, dosage and efficacy data
  • Detecting and outmaneuvering disease variables in study concept and execution
  • Quantifying, controlling, and capitalizing on the "human element" in the design and conduct of clinical trials
  • Maximizing operational efficiencies in drug delivery
  • Accelerating regulatory approval, market introduction, and market penetration.

  • "The pharmaceutical industry sails in turbulent, uncertain seas and urgently needs more effective ways to successfully navigate the increasingly complex maze of product development," said W. Neal Burnette, chief scientist, RedOak Logic Advisory Board.  "The sextant of this journey is one that can acquire all the information and data, filter it for relevancy, and plug it into a decision matrix to direct the path of drug development and enable real-time course corrections.  RedOak Logic is that sextant."

    AvailabilityRedOak's standard, base platform will reside on the cloud and the application interface will be customized to fit the business needs and culture of each company. Use-based pricing is anticipated. RedOak is currently working with Beta customers. Product availability is estimated for 2011.  For more information, contact Dale Fedewa, CEO (  

    About RedOak LogicRedOak Logic LLC is applying the Saffron Natural Intelligence Platform to help the $800 billion global pharmaceutical industry bring safer, more effective drugs to market faster and at lower cost.  The company's Advanced Decision Model Support platform will enable pharmaceutical companies to accelerate the clinical trials process, where "too much information" often impedes a company's operational efficiency.  By better utilizing the collective Experience hidden in business-critical public and private data, RedOak's solutions, built on Saffron 8, will enable better sense-making, decision support and predictive analytics, speeding decisions and improving time to market.  For more information about RedOak, email Dale Fedewa, CEO, at

    RedOak Logic.  Enabling Intelligence in Drug Development

    About The Saffron Natural Intelligence Platform Built on associative memory technology, Saffron is the new framework for Experience Management, the Business Intelligence of the future. Semantically connected, statistically rich with frequencies, free of traditionally bounded models of statistics and rules, and powered by service-oriented technology architecture, Saffron continuously identifies patterns and situations and creates memories of what's in the data.  As new data arrives, new memories are formed, so the "Experience" in your data can be captured and applied.  The Saffron Natural Intelligence Platform learns incrementally about connections and frequencies among people, places, things and events. The result is a multi-dimensional, non-parametric, massively scalable, connection engine capable of helping enterprises achieve new breakthroughs in real-time analysis, business intelligence and national security.

    About Saffron Technology Saffron helps business and IT leaders apply the collective Experience hidden in their data to better understand situational scenarios, determine best possible courses of action, and make higher value decisions about mission-critical issues.  Saffron's customers in academia, corporations and government are engaged in high-stakes research, financial services, risk management, supply chain operations, national security, health care, social media & marketing, and more.  SaffronSierra ( is a Platform-as-a-Service (PaaS) for developers creating new applications with the Saffron Natural Intelligence Platform, including SaffronMemoryBase™.  To learn more, visit

    Saffron Technology. The World of Experience.™MEDIA CONTACT:John SawyerThe Anvil-Chinook Agency

    SOURCE RedOak Logic LLC
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Decision Resources Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
    2. New FDLI Monograph Provides Expert Guidance on Selling Pharmaceuticals, Biologics to Federal Government
    3. Circle Biologics® Introduces Innovation in Medical Devices
    4. Pioneer® Surgical Expands Product Specialists to Support Growing Biologics Business
    5. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
    6. Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process
    7. Clive Dix Appointed as Chairman of Crescendo Biologics
    8. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
    9. PhRMA Statement Supporting Fair Incentives for Biologics Innovation
    10. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
    11. CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License
    Post Your Comments:
    (Date:12/1/2015)... BANGALORE, India and PITTSBURGH ... TASE: MYL) today announced that it expects to be ... developing country markets funded by international donors, TLE400 (Tenofovir ... Efavirenz 400 mg) for $99 per patient, per year. ... to develop TLE400. The significantly reduced price could generate ...
    (Date:12/1/2015)... , Dec. 1, 2015 Breg, Inc ... services, announced today that it has been awarded three ... Members served by Novation will have access to improved ... bracing products and soft goods dedicated to advancing orthopedic ... The aging U.S. population, rising prevalence of chronic ...
    (Date:12/1/2015)... N.J. , Dec. 1, 2015 ... against HIV/AIDS, Johnson & Johnson (NYSE: JNJ ... its Janssen Pharmaceutical Companies to significantly reduce the ... who make up 74 percent of new HIV ... Announced on World AIDS Day, these new initiatives ...
    Breaking Medicine Technology:
    (Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , one ... its iconic bottle has won top honors in Beverage World Magazine’s Global Packaging Design ... announced that it has been selected as a 2015 U.S.A. Taste Champion in the ...
    (Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015—Since the start ... scientific research and discoveries, leading us to better understand the disease’s behavior. Globally, ... affected by HIV/AIDS. Mediaplanet’s cross-platform edition of “World AIDS Day” provides insight on ...
    (Date:12/1/2015)... ... December 01, 2015 , ... ... optimization of adjunctive imaging is the focus of numerous abstracts accepted for presentation ... 29-December 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative ...
    (Date:12/1/2015)... WA (PRWEB) , ... December 01, 2015 , ... ... today that it has been selected as a finalist in this year’s Fierce ... and FierceMobileHealthcare. Next IT Healthcare was recognized as a finalist in the category ...
    (Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 - ... to head to Las Vegas for CES 2016, the world’s largest Consumer Electronic Show, ... Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture capitalist ...
    Breaking Medicine News(10 mins):